![](https://cdn.ibj.com/wp-content/uploads/2023/12/obesity-illio-120823-300x200.png)
Lilly launches obesity drug, but insurers balk over price
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.